EMJ are delighted to introduce Professor J. Brady Scott, Director of Clinical Education, Respiratory Care at Rush University, who provided an insight into their diverse and prestigious career as a respiratory therapist, researcher, and educator.

Histology is a key element for the multidisciplinary diagnosis of fibrotic diffuse parenchymal lung diseases (f-DPLD) when the clinical–radiological setting of f-DPLD with high-resolution CT features diagnostic of usual interstitial pneumonia (UIP) are not present.

The benefits of pulmonary rehabilitation (PR) diminish over 12–24 months following programme completion. A repeat PR programme may potentially prevent or reverse this decline in gains and may provide additional benefits.

The emergence of a new virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, in December 2019 triggered a global pandemic, forcing much of the world to adopt lockdown strategies and leading to extraordinary threats to the global healthcare system. The clinical manifestations of the disease, referred to as COVID-19, range from mild, self-limiting flu-like respiratory illness to life-threatening multi-organ failure and death.

Exposure to pollen has been associated with an increased risk of respiratory symptoms in both allergic and nonallergic individuals. However, the association of pollen exposure with respiratory symptoms during infancy, a particularly vulnerable period for lung development, remains unclear.

Kenya is home to a budding pharma sector, but the country still faces access to medicine challenges. What are they, and how can pharma help?

Nurses are vital healthcare team members and are often underutilised in antimicrobial stewardship (AS) activities. Several nursing responsibilities, such as taking allergy history and obtaining cultures, already overlap with AS activities.

The scientific community has made great strides in responding to the huge public health problems of obesity and diabetes with the discovery of the incretin system and the development of glucagon-like peptide 1 analogues.

A first-in-class vaccine for respiratory syncytial virus has shown to be highly efficacious in a Phase III trial, GSK has announced.